Avecho Biotechnology Limited (DUS:OEZ) Filings

Avecho Biotechnology Limited

Filings

FilingDateTypeFiled with
Avecho presents at BIO-EuropeNov 15, 2026Operations updateASX
September 2026 Quarterly Activities Report & Appendix 4COct 27, 2026Quarterly reportASX
September 2026 Quarterly Activities Report & Appendix 4COct 27, 2026Quarterly reportASX
Change of Chief Financial OfficerOct 27, 2026Other filingsASX
Response to ASX Price QueryOct 21, 2026Explanation requestASX
Response to ASX Price QueryOct 21, 2026Explanation requestASX
Avecho to present at the Canaccord Drug and Device ConfeOct 12, 2026Other filingsASX
Avecho to present at the ASX SMIDcaps ConferenceSep 22, 2026Other filingsASX
Avecho enters final stage of Phase III insomnia trialAug 30, 2026Operations updateASX
Appendix 4D and Half-year Financial ReportAug 25, 2026Interim reportASX
Avecho strengthens BD capability with senior appointmentAug 23, 2026Management or board changeASX
Small Holding Share Sale Facility CompletionAug 11, 2026Other filingsASX
Japanese patent granted for CBD capsuleAug 2, 2026Operations updateASX
June 2026 Quarterly Activities Report & Appendix 4CJul 28, 2026Quarterly reportASX
Positive interim results from Phase III insomnia programJun 23, 2026ResultsASX
Receipt of Research & Development Tax IncentiveMay 21, 2026FinancingASX
Avecho completes treatment for Phase III interim analysisMay 20, 2026Operations updateASX
Expiry of Listed OptionsMay 12, 2026FinancingASX
March 2026 Quarterly Activities Report & Appendix 4CApr 28, 2026Quarterly reportASX
Avecho completes recruitment for Phase III interim analysisMar 1, 2026Operations updateASX
Annual Report 31 December 2025Feb 27, 2026Annual reportASX
December 2025 Quarterly Activities Report & Appendix 4CJan 29, 2026Quarterly reportASX
Phase III CBD Clinical Trial Recruitment UpdateDec 17, 2025Operations updateASX
AVE Secures US & EU Patent Allowances for CBD Soft-GelDec 3, 2025Operations updateASX
September 2025 Quarterly Activities Report & Appendix 4COct 31, 2025Quarterly reportASX
Avecho raises $2.5m via placementOct 22, 2025FinancingASX
Appendix 4D and Half-year Financial ReportAug 28, 2025Interim reportASX
June 2025 Quarterly Activities Report & Appendix 4CJul 29, 2025Quarterly reportASX
Phase III Insomnia Trial Recruitment UpdateJul 28, 2025Operations updateASX
Receipt of R&D Tax IncentiveMay 28, 2025ResultsASX
Phase III Trial Update - New Sites Commence RecruitmentMay 19, 2025Operations updateASX
March 2025 Quarterly Activities Report & Appendix 4CApr 30, 2025Quarterly reportASX
Avecho receives initial US$3M upfront payment from SandozMar 27, 2025Other filingsASX
Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUSMar 2, 2025Acquisition or disposalASX
Trading HaltFeb 27, 2025Trading halt or suspensionASX
Appendix 4E - Preliminary Final ReportFeb 27, 2025ResultsASX
Response to ASX Price QueryFeb 14, 2025Explanation requestASX
December 2024 Quarterly Activities Report & Appendix 4CJan 30, 2025Quarterly reportASX
September 2024 Quarterly Activities Report & Appendix 4COct 28, 2024Quarterly reportASX
June 2024 Quarterly Activities Report & Appendix 4CJul 30, 2024Quarterly reportASX
Chair's Address and CEO PresentationMay 30, 2024Meeting outcomeASX
First Patient dosed in Phase III insomnia trialMay 15, 2024Operations updateASX
March 2024 Quarterly Activities Report & Appendix 4CApr 30, 2024Quarterly reportASX
Avecho commences Phase III insomnia trialMar 25, 2024Operations updateASX
Avecho meets TGA ahead of Phase III Clinical TrialMar 13, 2024Operations updateASX
AVE receives final ethics approval for Phase III CBD trialMar 6, 2024Operations updateASX
Appendix 4E and Annual Report 31 December 2023Feb 29, 2024Annual reportASX
December 2023 Quarterly Activities Report & Appendix 4CJan 30, 2024Quarterly reportASX
September 2023 Quarterly Activities Report & Appendix 4COct 30, 2023Quarterly reportASX
Reinstatement to Official QuotationAug 28, 2023Trading halt or suspensionASX
Avecho raises further $6M for Phase III trialAug 28, 2023FinancingASX
Voluntary SuspensionAug 24, 2023Trading halt or suspensionASX
June 2023 Quarterly Activities Report & Appendix 4CJul 24, 2023Quarterly reportASX
AVE CBD capsule passes two-year stability milestoneJun 21, 2023Other filingsASX
AVE adds TPM cannabinoid gummies to portfolioJun 6, 2023Other filingsASX
USPTO allows new TPM manufacturing patentMay 28, 2023Other filingsASX
Avecho licenses TPM for use in cancer drugsMay 22, 2023Other filingsASX
AVE commences manufacturing for Phase III trialMay 16, 2023Other filingsASX
Results of Entitlement OfferMay 8, 2023FinancingASX
March 2023 Quarterly Activities Report & Appendix 4CApr 27, 2023Quarterly reportASX
Investor PresentationApr 3, 2023Other filingsASX
ProspectusApr 3, 2023Offer documentASX
Entitlement Offer to raise $11m for Phase 3 clinical trialApr 3, 2023FinancingASX
Clinical CBD program expands with the Lambert InitiativeFeb 21, 2023Other filingsASX
December 2022 Quarterly Activities Report & Appendix 4CJan 30, 2023Quarterly reportASX
Athenex submits Avechos phytonadione to FDA pre-INDJan 12, 2023Other filingsASX
Avecho receives ethics approval for Phase III CBD trialDec 21, 2022Other filingsASX
AVE signs development agreement with PerrigoDec 19, 2022Other filingsASX
September 2022 Quarterly Activities Report & Appendix 4COct 27, 2022Quarterly reportASX
Increased CBD absorption in dogs vs commercial comparatorSep 19, 2022Other filingsASX
June 2022 Quarterly Activities Report & Appendix 4CJul 28, 2022Quarterly reportASX
Security Class Reinstatement to Quotation- AVEOJul 14, 2022Trading halt or suspensionASX
Update on Listed Options and Federal Court ApplicationJul 14, 2022Legal or regulatory actionASX
Suspension from Official Quotation - AVEOJun 8, 2022Trading halt or suspensionASX
March 2022 Quarterly Activities Report & Appendix 4CApr 28, 2022Quarterly reportASX
Positive results from AVEs topical CBD pain studyMar 28, 2022Other filingsASX
Dosing begins in topical CBD pain studyFeb 28, 2022Other filingsASX
Appendix 4E and Annual Report 31 December 2021Feb 27, 2022Annual reportASX
AVE license agreement for US recreational cannabis marketFeb 2, 2022Other filingsASX
December 2021 Quarterly Activities Report & Appendix 4CJan 30, 2022Quarterly reportASX
AVE Licenses CBD Soft-Gel to Medterra Pharma for ArthritisDec 20, 2021Other filingsASX
Positive results from Avechos Phase I trial of CBD soft-gelDec 7, 2021Other filingsASX
September 2021 Quarterly Activities Report & Appendix 4COct 28, 2021Quarterly reportASX
Topical CBD pain study with Lambert Initiative approvedOct 20, 2021Other filingsASX
Dosing begins in Phase I PK trial testing CBD soft-gelOct 3, 2021Other filingsASX
Phase I clinical trial testing CBD product-enrolment beginsSep 14, 2021Other filingsASX
June 2021 Quarterly Activities Report & Appendix 4CJul 26, 2021Quarterly reportASX
Avecho to Present New CBD Data at GCI Virtual SummitJun 8, 2021Other filingsASX
Chairs Address and CEO PresentationMay 31, 2021Other filingsASX
AB Vista to explore new TPM applications for Animal HealthMay 30, 2021Other filingsASX
TGA meeting for CBD soft-gel targeting insomniaMay 25, 2021Other filingsASX
Avecho completes pharmaceutical CBD soft-gel productMay 20, 2021Other filingsASX
March 2021 Quarterly Activities Report & Appendix 4CApr 28, 2021Quarterly reportASX
Avecho receives ethics approval for CBD human trialApr 12, 2021Other filingsASX
AVE receives firm commitment to raise $5.06 via placementFeb 9, 2021FinancingASX
December 2020 Quarterly Activities Report & Appendix 4CJan 29, 2021Quarterly reportASX
AVE begins Human Trial on CBD productDec 22, 2020Other filingsASX
Improved Propofol TPM Formulation Passes Toxicology StudyNov 3, 2020Other filingsASX
September 2020 Quarterly Activities Report & Appendix 4COct 28, 2020Quarterly reportASX
TPM Cannabinoid Development Program UpdateOct 18, 2020Other filingsASX
Progress Update for TPM Cannabinoid Development ProgramAug 19, 2020Other filingsASX
June 2020 Quarterly Activities Report & Appendix 4CJul 28, 2020Quarterly reportASX
March 2020 Quarterly Activities Report & Appendix 4CApr 28, 2020Quarterly reportASX
Changes to Leadership TeamApr 26, 2020Other filingsASX
Medicinal cannabis supply agreement with Tasmanian AlkaloidsApr 26, 2020Other filingsASX
Avecho signs Term Sheet for Cannabinoid Supply with PurisysApr 13, 2020Other filingsASX
Appendix 4E and Annual Report 31 December 2019Mar 1, 2020Annual reportASX
Appendix 4C - QuarterlyJan 22, 2020Quarterly reportASX
Injectable Portfolio Update - Products Differentiated by TPMDec 4, 2019Other filingsASX
Terumo return rights to TPM/Propofol InjectableOct 16, 2019Other filingsASX
Ashland purchases manufacturing rights for Vital ET and TPMJun 19, 2019Other filingsASX
FDA meeting provides guidance for TPM/Oxymorphone patchJan 17, 2019GuidanceASX
Reinstatement to Offical QuotationDec 18, 2018Other filingsASX
Phosphagenics and Mylan Agree SettlementDec 18, 2018Other filingsASX
Suspension from Official QuotationDec 11, 2018Trading halt or suspensionASX
Phosphagenics Arbitration Award IssuedNov 11, 2018Other filingsASX
Phosphagenics Receives Further Arbitration Process UpdateOct 22, 2018Other filingsASX
Phosphagenics Licensing Agreement UpdateSep 9, 2018Other filingsASX
Half Year AccountsAug 13, 2018Interim reportASX
AGM Chairmans Address and CEO PresentationMay 24, 2018Other filingsASX
Terumo Shifts Focus From Oxymorphone Patch to InjectablesMar 19, 2018Other filingsASX
Preliminary Final ReportFeb 27, 2018ResultsASX
Phosphagenics Placement Secures A$1.37 millionJan 17, 2018FinancingASX
Phosphagenics Receipt of R&D Tax IncentiveJan 16, 2018Other filingsASX
Phosphagenics Announces Results of Dairy TrialDec 21, 2017Other filingsASX
TPM Improves Negative Effects of Heat Stress in PoultryDec 14, 2017Other filingsASX
Phosphagenics Multinational License for TPM in Personal CareDec 3, 2017Other filingsASX
Phosphagenics Update on TPM/Propofol Development ProgramNov 8, 2017Other filingsASX
Phosphagenics Entitlement Offer Information BookletOct 3, 2017FinancingASX
Phosphagenics Announces Equity RaisingSep 26, 2017Other filingsASX
Phosphagenics Signs Term Sheet TPM Diclofenac Gel in AsiaSep 25, 2017Other filingsASX
Phosphagenics Market Update - Potential Return of CapitalSep 1, 2017Other filingsASX
June 2017 Half-year Financial Report and Appendix 4DAug 31, 2017Interim reportASX
Phosphagenics Signs Patch Development Agreement with TerumoAug 22, 2017Other filingsASX
Phosphagenics Sells BioElixia Brand to Pure Beauty AustraliaAug 9, 2017Other filingsASX
POH Mylan Arbitration Update- Expert Report on Damages FiledMay 28, 2017Other filingsASX
Phosphagenics and IAH Cease All PartnershipsMar 9, 2017Other filingsASX
Appendix 4E and Annual Financial ReportFeb 28, 2017Annual reportASX
Phosphagenics Non-Binding Term Sheet for OxyM Patch in JapanJan 30, 2017Other filingsASX
Phosphagenics Poultry Feed Study Reports Positive DataDec 14, 2016Other filingsASX
Reformulation TPM/Oxymorphone CompleteDec 11, 2016Other filingsASX
Phosphagenics ProPhase Arbitration Ruling Handed DownNov 16, 2016Other filingsASX
S&P DJ Indices Announces March Quarterly RebalanceNov 7, 2016Other filingsASX
Phosphagenics Updates Long Term Incentive SchemeSep 11, 2016Other filingsASX
Phosphagenics Begins Feed Efficiency Study in PoultryAug 31, 2016Other filingsASX
June 2016 Half-year Financial Report and Appendix 4DAug 25, 2016Interim reportASX
Phosphagenics Completes Grower/Finisher Pig StudyJun 29, 2016Other filingsASX
Phosphagenics Initiates Cattle StudyJun 1, 2016Other filingsASX
Phosphagenics Expands Licence Agreement for Diclofenac GelMay 18, 2016Other filingsASX
Phosphagenics Expands Japanese Option to Oxycodone PatchMay 17, 2016Other filingsASX
Phosphagenics Signs Japanese License Option and R&D AllianceApr 29, 2016Other filingsASX
Successful Results -Phase 2 TPM Trentinoin Gel Study on AcneMar 30, 2016Other filingsASX
June 2010 Half Yearly Appendix 4D and Financial ReportMar 30, 2016Interim reportASX
Appointment of Joint CEO - Dr Esra OgruMar 30, 2016Management or board changeASX
POH Global Agreement with Novartis Animal HealthMar 30, 2016Other filingsASX
Response to an ASX Price QueryMar 30, 2016Explanation requestASX
December 2009 Appendix 4E and Statutory Financial ReportMar 30, 2016ResultsASX
Phosphagenics Launches Australian Skincare ProductsMar 30, 2016Other filingsASX
Positive Results Phase 1B Study Transdermal Oxycodone PatchMar 30, 2016Other filingsASX
Trading haltMar 30, 2016Trading halt or suspensionASX
POH Ready to Commence Pivital Oxycodone Clinical TrialsMar 30, 2016Other filingsASX
June 2011 Half Yearly Appendix 4D and Financial ReportMar 30, 2016Interim reportASX
New National Stockist for ELIXIA Personal Care Product RangeMar 30, 2016Other filingsASX
Major Distribution Agreement for Asia for ELIXIA ProductsMar 30, 2016Other filingsASX
Elixia range of Personal Care Products - UpdateMar 30, 2016Other filingsASX
Launch of BodyShaper Cellulite Contour CremeMar 30, 2016Other filingsASX
Phosphagenics moves into lucrative hair marketMar 30, 2016Other filingsASX
Equity RaisingMar 30, 2016Other filingsASX
Phosphagenics to Partner Agricultural Company for ANZ marketMar 30, 2016Other filingsASX
Appendix 4E December 2010 Preliminary Final ReportMar 30, 2016ResultsASX
Phosphagenics collaboration to develop psoriasis drugMar 30, 2016Other filingsASX
Phosphagenics Collaborates With 3M To Develop Pain PatchMar 30, 2016Other filingsASX
POH: Anti-fat Peptide Patch progressesMar 30, 2016Other filingsASX
Preparation- pain patch manufacturing after positive resultsMar 30, 2016Other filingsASX
POH: Phosphagenics - Calzada - Exercise of optionMar 30, 2016Other filingsASX
Neura Therapeutik Appointed as US Strategic AdvisorsMar 30, 2016Other filingsASX
POH Further Refinements to Oxycodone Patch DesignMar 30, 2016Other filingsASX
POH adds David Jones as retail partner for Elixia productsMar 30, 2016Other filingsASX
POH Signs License Agreement with Intas PharmaceuticalsMar 30, 2016Other filingsASX
Korean Distribution Agreement for BioElixiaMar 30, 2016Other filingsASX
December 2011 Preliminary Final and Audited Financial ReportMar 30, 2016Other filingsASX
Pivotal TPM-oxycodone Patch Trials BeginMar 30, 2016Other filingsASX
Successful $24.1m Capital Raising and $3m SPPMar 30, 2016FinancingASX
Phosphagenics Pain Program UpdateMar 30, 2016Other filingsASX
Invoicing and Accounting Misappropriations InvestigationMar 30, 2016Legal or regulatory actionASX
Invoicing and Accounting IrregularitiesMar 30, 2016Other filingsASX
POH signs Agreement with Agricultural Research ServiceMar 30, 2016Other filingsASX
TPM/Diclofenac Gel - Themis in Supply Agmt with NovartisMar 30, 2016Other filingsASX
Oxymorphone Patch Meets Phase 1 End PointsMar 30, 2016Other filingsASX
December 2012 Appendix 4E and Audited Financial ReportMar 30, 2016ResultsASX
Oxycodone Patch UpdateMar 30, 2016Other filingsASX
Phosphagenics to Supply Firming Cream to GNCMar 30, 2016Other filingsASX
Oxycodone Patch Update - Development and Product ExpansionMar 30, 2016Other filingsASX
POH in JV to Supply TPM Equine Supplements to Golbal MarketMar 30, 2016Other filingsASX
POH Licences TPM Platform to Indian Pharmaceutical CompanyMar 30, 2016Other filingsASX
June 2014 App 4D Half Yearly Report and Financial ReportMar 30, 2016Interim reportASX
Opioid Patch Program UpdateMar 30, 2016Other filingsASX
POH Topical Oxycodone Patch Alleviates Pain in RacehorsesMar 30, 2016Other filingsASX
Enrolments Completed for Phase 2 Acne Treatment TrialMar 30, 2016Other filingsASX
December 2013 Appendix 4E - Annual Financial ReportMar 30, 2016Annual reportASX

This page holds 200 of 243 filings.